Johnson & Johnson (JNJ) continues to demonstrate resilience in the healthcare sector following its 2023 spinoff of Kenvue, with analysts maintaining a “buy” rating on the stock. Historically, JNJ has outperformed during economic downturns, evidenced by its relatively modest decline during the Great Recession and a swift recovery post-COVID-19 market slump. The company’s robust dividend, recently increased by 4.8% to $1.30 per share, underscores its financial stability, especially given its status as a Dividend King with 63 consecutive years of payout increases.
Despite some sales declines in key products like Stelara and Imbruvica, JNJ’s diverse portfolio, featuring 28 platforms generating over $1 billion in annual sales, has bolstered its profitability. The company is projecting a revenue increase to between $100 billion and $101 billion for 2025, alongside adjusted EPS growth. However, ongoing talc-related lawsuits and the impact of the Inflation Reduction Act present potential headwinds that could affect margins.
For market professionals, JNJ’s ability to navigate these challenges while maintaining strong growth metrics and a reliable dividend makes it a compelling stock in the healthcare sector.
Source: fool.com